Find Out More |
Looking to Buy: |
|
|
|
|
 Learn about the Liquid Extraction Surface Analysis (LESA) sample analysis system. LESA, based on Advion’s chip-based nanoelectrospray platform, the TriVersa NanoMate®, is used to provide direct Mass Spectrometric analysis of a variety of sample formats including tissue and organ samples, Thin Layer Chromatography (TLC) plates and other planar separation media, Dried Blood Spots (DBS), MALDI plates for complementary information and any other samples with extractable analytes.
The direct analysis of surfaces by mass spectrometry is a growing and powerful technique. The novel approach and design of the Advion LESA system enables, for the first time, the ability to couple direct analysis of surfaces with the power and breadth of chip-based nanoelectrospray. This simple-to-use combination allows for soft ionization, thereby preserving fragile molecules such as phase 2 metabolites and allowing unrivalled detection of drugs and their metabolites in tissue and organ samples. Researchers developing new forensic tools, novel drugs, better biofuels and technologies to strengthen homeland security now have a powerful new tool to use to analyze a variety of surfaces.
The new system was developed by Oak Ridge National Laboratory (ORNL), a multiprogram science and technology laboratory managed for the U.S. Department of Energy by UT-Battelle, which exclusively licensed the technology to AB SCIEX, a global leader in life science analytical technologies. In parallel, Advion signed an exclusive sublicense agreement with DH Technologies Development Pte. Ltd., an AB SCIEX affiliate, to commercialize certain discoveries and pending patents that leverage the Advion TriVersa NanoMate product lines used in the ORNL research in conjunction with AB SCIEX mass spectrometers.
“The launch of this innovative sample analysis system is extremely strategic for our company,” said David B. Patteson, CEO of Advion. “This is the result of our working closely with ORNL and AB SCIEX dating back nearly seven years to early discussions between Jack Henion – our Chairman and CSO – and our partners. We expect significant impact from our customers applying this technique to a myriad of sample types and conditions, which to date have been difficult to assay." back to top » |
clinical diagnostics
